Arcutis Biotherapeutics
ARQT
ARQT
63 hedge funds and large institutions have $1.02B invested in Arcutis Biotherapeutics in 2020 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 31 increasing their positions, 10 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
63
Holders Change
+7
Holders Change %
+12.5%
% of All Funds
1.27%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.06%
New
11
Increased
31
Reduced
10
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
BlackRock
New York
|
+$14.4M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.1M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.8M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$2.4M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.31M |
Top Sellers
| 1 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$5.44M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$5.16M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
-$2.93M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.21M |
| 5 |
Renaissance Technologies
New York
|
-$838K |
